MapLight Therapeutics

MapLight Therapeutics is a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) disorders. The company was founded by recognized leaders in psychiatry and neuroscience research and uses a circuit-driven discovery platform to identify neural circuits causally linked to disease and target them for therapeutic modulation. Its pipeline includes ML-007C-MA, an M1/M4 muscarinic agonist co-formulated with a peripherally acting anti-cholinergic, being developed for schizophrenia (Phase 3-ready after positive Phase 2 ZEPHYR results) and Alzheimer's disease psychosis (Phase 2 VISTA trial ongoing with Fast Track designation); ML-004, a 5-HT1B/1D agonist in Phase 2 for autism spectrum disorder irritability; ML-009, a GPR52 positive allosteric modulator in preclinical development for hyperactivity/impulsivity; ML-055, a next-generation M1/M4 agonist for neuropsychiatric disorders; and ML-021, an M4 antagonist for Parkinson's disease. The company trades on Nasdaq under the ticker MPLT. Updated Aug 13, 2026